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Background: In non-valvular atrial fibrillation (NVAF) patients, congestive heart failure (CHF)
confers an increased risk of stroke or systemic thromboembolism. This risk is present in both
heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction
(HFpEF). It is unclear if clinicians account for both types of CHF in their NVAF anticoagulation
practices. Accordingly, we characterized current outpatient anticoagulation trends in NVAF
patients with HFpEF compared to patients with HFrEF.
Methods: The outpatient NCDR PINNACLE-AF registry was analyzed to identify patients with
NVAF and CHF. The study population was subdivided into HFpEF (ie, LVEF ≥ 40%) and HFrEF
(LVEF < 40%). Anticoagulation rates by CHF group were compared and stratified by CHA2DS2-
VASc score.
Results: A total of 340 127 patients with NVAF and CHF were identified, of whom 248 136
(73.0%) were classified as HFpEF and 91 991 (27.0%) as HFrEF. Patients with HFpEF had higher
mean CHA2DS2-VASc scores and were more likely to be female, older, and have hypertension
(P < 0.001). Unadjusted anticoagulation rates were significantly lower in patients with HFpEF
compared to those with HFrEF (60.6% vs 64.2%, respectively). Lower rates of anticoagulation in
the HFpEF group persisted after risk adjustment (RR: 0.93 [95% CI: 0.91, 0.94]). Stratification by
CHA2DS2-VASc score demonstrated that lower rates of anticoagulation in patients with HFpEF
persisted until a score of ≥5.
Conclusions: Patients with NVAF and HFpEF have significantly lower anticoagulation rates
when compared to their HFrEF counterparts. These findings suggest a potential underapprecia-
tion of HFpEF as a risk factor in patients with NVAF.
KEYWORDS
anticoagulation, atrial fibrillation, congestive heart failure, heart failure with preserved ejection
fraction, heart failure with reduced ejection fraction
1 | INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia, with a
reported 2% prevalence among all medicare beneficiaries <65 years
old and 9% ≥65 years old, and an estimated 2-10% annual stroke risk
depending on individual risk factors.1,2 Anticoagulation strategies for
reducing the incidence of cerebral and systemic thromboembolism in
the setting of non-valvular AF (NVAF) have relied on risk score sys-
tems including the CHADS2 and the more current CHA2DS2-VASc
scores. The CHA2DS2-VASc score, which has more discriminatory
power in individuals characterized as low risk by CHADS2, was
described and validated in 2009, and defines congestive heart failure
(CHF) as a left ventricular ejection fraction (LVEF) ≤40%, or signs or
symptoms of right or left heart failure (HF).1,3–5 The American College
of Cardiology/American Heart Association/Heart Rhythm Society
ABBREVIATIONS: CAD, coronary artery disease; CI, confidence interval; CHF,
congestive heart failure; DM, diabetes mellitus; HFrEF, heart failure with
reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction;
HTN, hypertension; LVEF, left ventricular ejection fraction; NVAF, non-valvular
atrial fibrillation; RR, relative risk; TIA, transient ischemic attack.
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(ACC/AHA/HRS) and European Society of Cardiology (ESC) all recom-
mend using the CHA2DS2-VASc score to risk stratify individuals with
AF to inform anticoagulation decisions.2,5 Specifically, the 2014
AHA/ACC/HRSA Guidelines for the Management of Patients with AF
recommend (Class I) all individuals with a history of prior stroke or
TIA, or CHA2DS2-VASc score of ≥2 be considered for anticoagulation
based on their bleeding risk, while the 2016 ESC Guidelines for the
Management of AF recommends anticoagulation in females with a
CHA2DS2-VASc score ≥ 2 and males with a score ≥ 1.
1,5
Even though congestive HF has been validated as an indepen-
dent risk factor for stroke regardless of ejection fraction, the clinical
significance of HF with preserved ejection fraction (HFpEF) may be
underappreciated. Approximately, 50% of all patients with HF have
HFpEF, with cross-sectional studies reporting rates between 40% to
71% depending on the EF cutoff (40%-50%) used to define HFpEF,
and longitudinal studies showing an increasing prevalence over
time.6–11
Practice patterns regarding the prescription of anticoagulation for
patients with NVAF and HFpEF or HFrEF have not been well charac-
terized and guideline adherence remains unknown. Prior studies in the
HF population have reported varying rates of anticoagulation in those
with NVAF, with one meta-analysis that aggregated unadjusted data
from 10 studies showing lower rates in the HFpEF compared to the
HFrEF population, and another study, which showed after risk adjust-
ment, equal rates of anticoagulation in inpatients with HFpEF or
HFrEF (11, 17). The aim of this study was to characterize current out-
patient practice patterns regarding the use of anticoagulation in a
large cohort of outpatient patients with NVAF and CHF. By character-
izing rates of oral anticoagulation in patients with HFpEF compared to
HFrEF, we hope to identify gaps between practice patterns and antic-
oagulation guidelines in patients with AF and HF.
2 | METHODS
2.1 | Data collection
We retrospectively analyzed a series of 6 746 301 consecutive
patients who were prospectively entered into the American College
of Cardiology (ACC), National Cardiovascular Data Registry (NCDR),
and Practice Innovation and Clinical Excellence (PINNACLE) outpa-
tient data registry between January 1 2008 to June 30 2016. The
NCDR PINNACLE-AF registry is a verified, peer-reviewed data collec-
tion system that includes national adult outpatient visits. The initial
study population included 452 483 patients with NVAF and CHF.
Patients with incomplete left ventricular assessment (n = 110 931),
any contraindication to therapeutic oral anticoagulation (n = 1161), or
missing demographic data (n = 328) were excluded (Figure 1). The
final study population included 340 127 patients. Patient demo-
graphics and risk factors, baseline clinical characteristics, use of antic-
oagulation, and assessment of left ventricular function were obtained
from the last outpatient visit during the January 1 2008 to June
30 2016 study period.
2.2 | Definitions and study endpoints
The primary predictor variable was CHF group, with patients classified
into two subgroups: HFpEF (LVEF ≥ 40%) and HFrEF (LVEF < 40%). The
EF cutoff of 40% was chosen to differentiate between HFpEF and HFrEF
because this was used as the objective definition of HF in the CHA2DS2-
VASc score. In addition, although epidemiological studies characterizing
HFpEF have had variable definitions for HFpEF (>40% vs >50%), reduced
EF was consistently defined as <40%.6–10 LVEF was obtained from elec-
tronic medical record data. CHF was defined as either symptoms or phys-
ical exam findings consistent with heart failure, a prior hospitalization
with HF as a primary diagnosis, or an LVEF <40%. Patients without LVEF
were excluded from the analysis as described above.
The CHA2DS2-VASc score was calculated for each patient. One
point was assigned for the presence of peripheral vascular disease,
CHF, diabetes mellitus (DM), hypertension (HTN) and age 6 to
-74 years. Two points were assigned if prior history of stroke/TIA or
age ≥ 75 years old. As per the NCDR PINNACLE-AF registry data
standards, CHF was defined as symptoms of HF including dyspnea,
orthopnea, rales, edema, S3, S4, ascites, or JVD, LVEF <40%, or exac-
erbation of CHF requiring hospitalization. In addition, vascular disease
is defined as the presence of peripheral arterial disease, peripheral
vascular disease, history of myocardial infarction, and prior interven-
tional, or surgical revascularization.12
The main outcome parameter of the present study was rates of
oral anticoagulation defined as warfarin, dabigatran, rivaroxaban, apixa-
ban, or edoxaban. To better characterize how stroke risk and guideline
recommendations impact rates of anticoagulation, secondary analyses
included stratification by: (a) CHA2DS2-VASc score, (b) CHA2DS2-VASc
≤1 compared to CHA2DS2-VASc ≥2, and (c) history of TIA or stroke
compared to no prior TIA or stroke.1 To test the robustness of the
results, sensitivity analysis excluding those on dual antiplatelets was
done. In addition, to understand trends in anticoagulation over time,
temporal analysis over the study period was conducted.
FIGURE 1 Flow chart of the study population. This flow chart shows
how the study population was derived. HFpEF, heart failure with
preserved ejection fraction; HFrEF, heart failure with reduced ejection
fraction; LV left ventricle
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2.3 | Statistical analysis
Continuous variables were reported as mean ± SD and compared
using the Student's t test. Categorical variables were reported as per-
centages and compared using the χ2 test or Fisher exact test. Given
the large sample size, standardized differences between groups were
calculated to report effective size to help with interpreting statistically
significant differences. Standardized differences of <0.1 are generally
considered to represent an insignificant effective size.13 Univariate,
bivariate, and multivariable logistic regression analyses were per-
formed to assess the effect of HF type (ie, HFrEF or HFpEF),
CHA2DS2-VASc, age, gender, body mass index, prior revascularization,
coronary artery disease, prior myocardial infarction, cerebral thrombo-
embolism, peripheral arterial disease, systemic thromboembolism,
HTN, or DM on rates of anticoagulation. In the temporal analysis, HF
type, year of last outpatient visit and respective interaction terms
were included in the logistic regression model. The models accounted
for clustering of patients by practice by using generalized estimating
equations. To directly estimate risk ratios, Zou's method was used by
specifying a Poisson distribution and including a robust variance esti-
mate in the models. The risk-adjusted anticoagulation rates were cal-
culated using the ratio of observed: expected rates of anticoagulation.
Summing the resultant coefficients from the function of independent
variables included in the model estimated the individual risk probabili-
ties of anticoagulation. The total expected rate of anticoagulation is
derived by summing the individual risk probabilities for anticoagula-
tion. The risk-standardized anticoagulation rates were then calculated
by multiplying the observed: expected rates by the average anticoagu-
lation rate for the entire population. All reported P-values are two-
sided. All data were analyzed using the statistical software package,
SAS version 9.4 (SAS Institute, Cary, North Carolina). The Harvard
Clinical Research Institute completed the analysis for this study.
3 | RESULTS
3.1 | Study population
A total of 340 127 patients with congestive HF and NVAF were
included in the study. Of these, 248 136 (73.0%) and 91 991 (27.0%)
were identified as patients with HFpEF and HFrEF, respectively.
Table 1 shows all patient variables stratified by HF groups.
Patients with HFpEF were significantly older (76.0 ± 11.4 vs
73.8 ± 11.8 years), more likely to be female (45.5% vs 26.6%) and had
significantly higher body mass indexes (BMI) (29.5 ± 6.6 vs 28.6 ± 6.2
kg/m2) than patients with HFrEF. CHA2DS2-VASc score was signifi-
cantly higher in patients with HFpEF. This was mainly driven by
female gender, age, and hypertension (88.7% vs 81.4%, P < 0.001). In
contrast, individuals with HFrEF were more likely to have higher rates
of surrogates of ischemic heart disease including coronary artery dis-
ease, prior history of myocardial infarction, previous coronary artery
bypass graft, or being on dual antiplatelet therapy. For the remaining
risk factors, there was a statistically significant difference in frequency
between both groups, but standardized differences were less than
0.1, suggesting a small effect.
Overall unadjusted rates of anticoagulation were higher in the
HFrEF group compared to the HFpEF group (64.2% vs 60.6%), even
though mean CHA2DS2-VASc score was higher in the HFpEF group
(P < 0.001). After controlling for patient demographics, clinical vari-
ables, and CHA2DS2-VASc components, individuals with HFpEF still
remained significantly less likely to be anticoagulated than those with
HFrEF (RR 0.93, 95% CI 0.91-0.94). Age, BMI, HTN, previous cerebral
or systemic thromboembolism, and prior percutaneous revasculariza-
tion were all associated with increased rates of anticoagulation. Vari-
ables such as the use of dual antiplatelet therapy, prior myocardial
infarction, and surgical revascularization were associated with lower
rates of anticoagulation (Figure 2). These relationships persisted after
exclusion of patients on dual antiplatelet therapy.
3.2 | Secondary analyses
3.2.1 | CHA2DS2-VASc
Analysis stratified by CHA2DS2-VASc score showed lower observed
rates of anticoagulation in HFpEF compared to HFrEF until CHA2DS2-
VASc score was 5 or greater. This relationship persisted even after risk
adjustment, with the difference in anticoagulation rates being the
greatest in the CHA2DS2-VASc of 1 group and decreasing with each
subsequent CHA2DS2-VASc score until 5 (Figure 3). In the multivari-
able model that included only the CHA2DS2-VASc components,
increasing age, history of HTN, DM, stroke/TIA, or thromboembolism
were all associated with increased use of anticoagulation (P < 0.001).
Female gender and vascular disease were associated with lower rates
(P < 0.001). See Table S1, Supporting Information for the CHA2DS2-
VASc component risk-adjusted relative risks for anticoagulation.
Based on the AHA/ACC/HRSA recommendations that all individ-
uals with a CHA2DS2-VASc score of 2 or more, or history of stroke/
TIA should be anticoagulated, separate analyses stratified by these
groups were done. In the analysis stratified by CHA2DS2-VASc
score < 2 vs ≥2, the largest difference in unadjusted rates of anticoa-
gulation between CHF groups was observed in individuals with a
CHA2DS2-VASc score of 1 (n = 4568), which in this study population
were males with CHF as their sole thromboembolic risk factor. Indi-
viduals with HFpEF were less likely to be anticoagulated compared to
those with HFrEF (46.1% vs 68.3%, P < 0.001). This relationship per-
sisted after risk adjustment (RR 0.71, 95% CI 0.66-0.76). Those on
dual antiplatelet therapy were also less likely to be anticoagulated as
expected (RR 0.52, 95% CI 0.35-0.76). A larger BMI (RR 1.1, 95% CI
1.07-1.13) and age (RR 1.18, 95% CI 1.14-1.22) were both associated
with increased rates of anticoagulation. Among patients with
CHA2DS2-VASc ≥2 (n = 335 559), individuals with HFpEF were simi-
larly less likely to be anticoagulated compared to those with HFrEF
(60.7% vs 64.1%, P < 0.001); however, the difference between antic-
oagulation rates was markedly smaller. This relationship persisted
after risk adjustment (RR 0.93, 95% CI 0.92-0.94). Risk factors associ-
ated with anticoagulation were not different from those found in the
primary analysis.
3.2.2 | STROKE or TIA
In the sub-analysis stratified by history of stroke/TIA, those with prior
stroke/TIA (n = 76 143) were older (76.4 years vs 75.1 years)
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compared to those without prior stroke/TIA (n = 263 984). As
expected the prior stroke/TIA cohort were also more likely to have car-
diovascular risk factors including CAD, systemic embolism, prior revas-
cularization, peripheral artery disease, HTN, DM, dyslipidemia, and
chronic kidney disease, as well as higher rates of dual antiplatelets.
Rates of anticoagulation in those with a prior history of stroke/TIA
remained higher in the HFrEF group compared to the HFpEF group
(65.3% vs 62.0%, RR 0.94, CI 0.92-0.96, P < 0.001) even after control-
ling for risk factors. Risk factors associated with anticoagulation were
similarly not different from those found in the primary analysis.
TABLE 1 Baseline characteristics by heart failure group
Variable NVAF + CHF HFpEF HFrEF Standardized difference P-value
Count 305 223 210 917 (69%) 94 306 (31%) — —
Age (years) 75.4 ± 11.6 76.0 ± 11.4 73.8 ± 11.8 0.190 <0.001
Male 59.6% 54.5% 73.4% −0.402 <0.001
BMI (kg/m2) 29.2 ± 6.5 29.5 ± 6.6 28.6 ± 6.2 0.131 <0.001
Hypertension 294 912 (86.7%) 220 065 (88.7%) 74 847 (81.4%) 0.206 <0.001
Diabetes 106 840 (31.4%) 76 591 (30.9%) 30 249 (32.9%) −0.043 <0.001
CKD 31 108 (9.1%) 21 758 (8.8%) 9350 (10.2%) −0.048 <0.001
TIA/stroke 76 143 (22.4%) 56 914 (22.9%) 19 229 (20.9%) 0.049 <0.001
Systemic TE 4990 (1.5%) 3486 (1.4%) 1504 (1.6%) −0.019 <0.001
Previous MI 84 940 (25.0%) 55 391 (22.3%) 29 549 (32.1%) −0.221 <0.001
CAD 236 023 (69.4%) 165 753 (66.8%) 70 270 (76.4%) −0.214 <0.001
PCI 70 887 (20.8%) 50 500 (20.4%) 20 387 (22.2%) −0.044 <0.001
CABG 62 909 (18.5%) 41 434 (16.7%) 21 475 (23.3%) −0.167 <0.001
NYHA class <0.001
I 46 406 (13.6%) 40 818 (16.4%) 5588 (6.1%) 0.333 —
II 41 388 (12.2%) 30 379 (12.2%) 11 009 (12.0%) 0.008 —
III 17 060 (5.0%) 10 351(4.2%) 6709 (7.3%) −0.135 —
IV 1973 (0.6%) 1076 (0.4%) 897 (1.0%) −0.065 —
Dyspnea 208 697 (61.4%) 155 048 (62.5%) 53 649 (58.3%) 0.085 <0.001
Orthopnea 52 847 (15.5%) 38 005 (15.3%) 14 842 (16.1%) −0.022 <0.001
Rales 23 398 (6.9%) 16 581 (6.7%) 6817 (7.4%) −0.028 <0.001
Edema 151 711 (44.6%) 113 223 (45.6%) 38 488 (41.8%) 0.076 <0.001
S3Gallop 21 443 (6.3%) 13 936 (5.6%) 7507 (8.2%) −0.101 <0.001
S4Gallop 29 107 (8.6%) 20 924 (8.4%) 8183 (8.9%) −0.016 <0.001
Ascites 2754 (0.8%) 1799 (0.7%) 955 (1.0%) −0.034 <0.001
JVD 22 522 (6.6%) 14 884 (6.0%) 7638 (8.3%) −0.090 <0.001
LVEF (%) 3.439 <0.001
Mean ± SD 48.7 ± 15.1 56.1 ± 9.0 28.0 ± 7.3 — —
Median (IQR) 52.0(38.0,60.0) 55.0(50.0,61.0) 30.0(23.0,35.0) — —
CHA2DS2-VASc
Mean ± SD 5.0 ± 1.6 5.0 ± 1.6 4.7 ± 1.6 0.205 <0.001
1 4568 (1.3%) 2737 (1.1%) 1831 (2.0%) −0.072 —
2 19 323 (5.7%) 12 666 (5.1%) 6657 (7.2%) −0.089 —
3 38 543 (11.3%) 25 910 (10.4%) 12 633 (13.7%) −0.101 —
4 67 848 (19.9%) 47 659 (19.2%) 20 189 (21.9%) −0.068 —
5 90 328 (26.6%) 67 248 (27.1%) 23 080 (25.1%) 0.046 —
6 60 369 (17.7%) 45 934 (18.5%) 14 435 (15.7%) 0.075 —
7 35 886 (10.6%) 27 522 (11.1%) 8364 (9.1%) 0.066 —
8 18 882 (5.6%) 14 785 (6.0%) 4097 (4.5%) 0.068 —
9 4380 (1.3%) 3675 (1.5%) 705 (0.8%) 0.068 —
DAPT 38 812 (11.4%) 25 554 (10.3%) 13 258 (14.4%) −0.125 <0.001
Aspirin 200 510 (59.0%) 143 172 (57.7%) 57 338 (62.3%) −0.095 <0.001
P2Y12 49 551 (14.6%) 32 841 (13.2%) 16 710 (18.2%) −0.136 <0.001
BMI, body mass index; CABG, coronary artery bypass graft; CAD coronary artery disease; DAPT, dual antiplatelet therapy; IQR, interquartile range; JVD,
jugular venous distention; LVEF, left ventricular ejection fraction; MI myocardial infarction; NYHA, New York Heart Association; PCI percutaneous coro-
nary intervention; TIA transient ischemic attack; TE thromboembolism.
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3.2.3 | Anticoagulation over time
Unadjusted rates of anticoagulation have increased in both HFrEF and
HFpEF groups over time, with higher rates of anticoagulation in the
HFrEF group compared to the HFpEF group in all years except for
2008 (Figure 4). In the HFpEF group, anticoagulation rates increased
by ~5.8% yearly (RR: 1.042, CI 1.031-1.054, P < 0.001) and in the
HFrEF group ~ 4.2% yearly (RR: 1.042, CI 1.031, 1.054).
4 | DISCUSSION
Within our outpatient study population of individuals with NVAF and
CHF, 69% of these patients had HFpEF. Although this falls within the
upper range of what has been previously reported,6–10 the outpatient
study cohort used was contemporary and is consistent with prior
studies suggesting that HFpEF is a growing clinical entity. Importantly,
our study showed that although HFpEF patients with NVAF had
higher average CHA2DS2-VASc scores, their overall rates of anticoa-
gulation compared to their HFrEF counterparts were lower. Thus,
even though data from observational studies and clinical trials show
comparable rates of stroke/TIA within the reduced and preserved
ejection fractions HF groups with AF,14–16 there remains a discrep-
ancy in rates of anticoagulation between these groups in the outpa-
tient. Importantly, even though HFpEF patients are less likely to be
anticoagulated than HFrEF patients, rates of anticoagulation in both
groups has increased over time.
Prior studies evaluating rates of anticoagulation in HF patients
with AF have shown variable anticoagulation rates depending on the
FIGURE 2 Relative risks for oral anticoagulation by baseline patient characteristics. Relative risks from the variables included in the multivariable
model for predicting anticoagulation. CABG, coronary artery bypass graft; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart
failure with reduced ejection fraction, PCI percutaneous coronary intervention, TIA, transient ischemic attack
FIGURE 3 Risk adjusted rates of anticoagulation by heart failure group and CHA2DS2-VASc score. HFpEF, heart failure with preserved ejection
fraction; HFrEF heart failure with reduced ejection fraction
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study population evaluated and whether or not the data were risk
adjusted.6,14,15 In one observational study by Steinberg et al. which
used inpatient registry data, lower unadjusted rate of anticoagulation
in the HFpEF group compared to the HFrEF group resolved after risk
adjustment.6 In the Sartipy et al study which used inpatient and out-
patient data unadjusted rates of anticoagulation in patients with
HFrEF were higher compared to those with HFpEF.15 Interestingly,
this study found in multivariable analysis that anticoagulant use in
patients with HFpEF was more likely to be associated with NVAF than
in patients with HFrEF.15 This suggests that the HFrEF population
may be more likely to have additional indications for anticoagulation
compared to the HFpEF group, and may be why differences in antic-
oagulation rates between these two groups decrease after risk
adjustment.
Our study provides insight into current outpatient anticoagulation
patterns in patients with HF and AF. Although it is unclear why patients
with HFpEF are less likely to be anticoagulated than those with HFrEF,
this difference suggests that opportunities for improving rates of antic-
oagulation in this patient population exist. Central to the pathogenesis
of HFpEF is the systemic inflammation resulting from the comorbid
conditions including obesity, DM, HTN, and renal failure associated
with it.17 Because of its heterogeneity, it is possible that patients with
HFpEF are being underdiagnosed and therefore undertreated. Sugges-
tive of this, was how the difference in anticoagulation prescription
between HF groups narrowed as CHA2DS2-VASc score increased. Spe-
cifically, in the CHA2DS2-VASc = 1 group the difference in the risk-
adjusted rates of anticoagulation was nearly 20%, but decreased to
1.5% by CHA2DS2-VASc = 4 before becoming and staying insignificant
by CHA2DS2-VASc ≥5. This discrepancy in the CHA2DS2-VASc = 1
may be because a diagnosis of HFpEF may be more nuanced than
HFrEF, and the accurate categorization of HFpEF may be more difficult
for unexperienced clinicians. Contributing to these differences in antic-
oagulation rates may also be that the major guideline recommendations
are less stringent in this lower risk group. Specifically, the
ACC/AHA/HRS only recommends consideration of anticoagulation,
aspirin or no antithrombotic therapy in individuals with a CHA2DS2-
VASc score of 1, and the ESC only recommends anticoagulation in
males with CHA2DS2-VASc score of 1. Regardless, a greater awareness
of the stroke risk that HFpEF confers in NVAF may be needed.
In the analysis stratified by AHA/ACC/HRSA indications for
anticoagulation in AF, specifically CHA2DS2-VASc score 2 or
greater, or prior stroke/TIA, less than two-third of individuals who
met a Class I indication for anticoagulation were being anticoagu-
lated. Future studies should be aimed at further discriminating stro-
ke/TIA risk in individuals categorized as low-risk based on our
current risk scores, so that standardized recommendations for antic-
oagulation can be made.
Our study has several limitations. This study involved an outpa-
tient data registry that relies on manual entry and standardized algo-
rithms for extracting data from the electronic medical records, so data
completion was not 100%. Thus, the results only characterize outpa-
tient patterns of anticoagulation prescription and are not generalizable
to the entire population. In addition, HF classification relied on both
quantitative and qualitative assessments of ejection fraction, and mis-
classification may have occurred. In addition, because this is not a pro-
spective dataset being collected for the hypothesis being evaluated,
there are data constraints including an inability to assess patient pref-
erences, as well as other indications for anticoagulation, such as deep
venous thromboembolism in our dataset. Resultantly, it was not possi-
ble to discriminate between and exclude individuals who had a contra-
indication to anticoagulation or an indication to anticoagulation other
than AF in this dataset. Instead, as is convention with analyses using
the PINNACLE dataset, we relied on a data field indicating medical
contraindication to anticoagulation to exclude individuals from analy-
sis. Longitudinal data was also not present, and instead only a snap-
shot of anticoagulation rates could be provided, and no outcomes
data including rates of stroke/TIA, or medication adherence was
available.
FIGURE 4 Observed rates of anticoagulation by heart failure group and year. This graphic shows the temporal trend in observed rates of
anticoagulation in the congestive heart failure population (total and by heart failure group) with non-valvular atrial fibrillation. Comparison
between the observed rates of anticoagulation between the heart failure groups by year were made. *P < 0.05, HFpEF, heart failure with
preserved ejection fraction; HFrEF heart failure with reduced ejection fraction
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5 | CONCLUSIONS
The majority of outpatients with NVAF and CHF have HFpEF, and
even though these individuals have higher CHA2DS2-VASc scores,
they are significantly less likely to be prescribed oral anticoagulation
compared to HFrEF patients. The discrepancy in anticoagulation rate
is most prevalent in the lower risk groups, and may be secondary to
differences in guideline recommendations and evidence for anticoagu-
lating individuals when bleeding is a risk. Future studies are needed to
clarify why differences exist in anticoagulation by HF type; however,
our data calls for educating and alerting clinicians of this important
risk factor for stroke prevention.
6 | CLINICAL PERSPECTIVES
Congestive HF has been validated as an independent risk factor for
stroke regardless of ejection fraction; however, the clinical signifi-
cance of HF with preserved EF may be underappreciated. The major-
ity of outpatients with NVAF and congestive HF have preserved
ejection fraction. Even though these individuals have higher
CHA2DS2-VASc scores, they are significantly less likely to be pre-
scribed oral anticoagulation compared to outpatients with HF with
reduced EF which suggests an opportunity for educating and alerting
clinicians of this important risk factor for stroke prevention.
7 | TRANSLATIONAL OUTLOOK
Future studies are needed to clarify why differences exist in anticoa-
gulation by HF type, and in particular why individuals with AF and HF
with preserved EF are less likely to anticoagulated than their reduced
EF counterparts.
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